T1	SectionAnnotate 2881 2898	INTERVAL HISTORY:
T2	SectionAnnotate 3140 3143	ROS
T3	SectionSkip 3211 6006	Current Outpatient Medications   Medication Sig Dispense Refill    butenafine (LOTRIMIN ULTRA) 1 % cream       cholecalciferol, vitamin D3, 1000 UNITS TAB tablet Take 4 tablets by mouth daily         clotrimazole (MYCELEX) 10 mg troche 1 tablet (10 mg total) by Other route 3 (three) times daily Take by buccal route. Take for 14 days and during chemotherapy cycles after initial treatment 90 Troche 1    fluconazole (DIFLUCAN) 100 mg tablet Take 200mg PO qd on day one followed by 100mg PO qd on subsequent days.  Take for 1 week and then stop. 8 tablet 0    hyoscyamine (LEVSIN/SL) 0.125 MG SL tablet Place 1 tablet (0.125 mg total) under the tongue every 4 (four) hours as needed 
 (abdominal cramping). (Patient not taking: Reported on 09/17/2019  ) 60 tablet 3    KERYDIN 5 % SolA       L.acidoph/B.long/L.plant/B.lac (PROBIOTIC ACIDOPHILUS BEADS ORAL) Take by mouth.      lidocaine-prilocaine (EMLA) 2.5-2.5 % cream Apply cream one hour before port access as needed for pain. 30 g 2    lipase-protease-amylase (CREON) 24,000-76,000 -120,000 unit capsule Take 2 tabs with meals and 1 tab with snacks. 300 capsule 5    loperamide (IMODIUM) 2 mg capsule Take two capsules by mouth at the onset of diarrhea, then take one capsule every 2 hours until diarrhea-free for 12 hours. 30 capsule 5    medical cannabis       ondansetron (ZOFRAN) 8 mg tablet Take 1 tablet three times a day as needed for nausea and vomiting. Start 2 days after last dose of palonosetron (Aloxi) is given. (Patient not taking: Reported on 07/25/2019  ) 30 tablet 5    oxyCODONE (OXYCONTIN) 10 mg 12 hr ER tablet Take 1 tablet (10 mg total) by mouth every 12 (twelve) hours (Patient not taking: Reported on 09/17/2019  ) 60 tablet 0    oxyCODONE (ROXICODONE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 4 (four) hours as needed for Pain (for moderate to severe pain). (Patient not taking: Reported on 09/17/2019  ) 90 tablet 0    prochlorperazine (COMPAZINE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 6 (six) hours as needed (nausea and vomiting). (Patient not taking: Reported on 09/17/2019  ) 30 tablet 5    rivaroxaban (XARELTO) 20 mg tablet Take 1 tablet (20 mg total) by mouth daily 30 tablet 5    terbinafine HCl (LAMISIL) 1 % cream Apply topically Daily. Use as instructed      TURMERIC ORAL Take by mouth      UNABLE TO FIND Take 1 tablet by mouth Host Defense brand "Stamets 7" Daily Immune Support, one tablet every other day during weeks of no infusion.   Each tablet contains 71.5 mg of royal sun blazei, cordyceps, reishi, maitake, lion's mane, chaga, and mesima.        UNABLE TO FIND Take by mouth Host 
 Defense brand Turkey Tail extract, ~ 0.5 ml every other day during weeks of no infusion       No current facility-administered medications for this visit.
T4	SectionSkip 6014 6073	ALLERGIES:  Allergies/Contraindications  No Known Allergies
T5	SectionSkip 6190 6275	PHYSICAL EXAM:  Objective   Vital Signs:   There were no vitals filed for this visit.
T6	SectionSkip 6597 6613	Laboratory data:
T7	SectionSkip 6616 7233	Lab Results   Component Value Date    WBC Count 6.4 09/03/2019    Neutrophil Absolute Count 4.18 09/03/2019    Hemoglobin 11.4 (L) 09/03/2019    Hematocrit 35.4 (L) 09/03/2019    Platelet Count 126 (L) 09/03/2019    Creatinine 0.74 09/03/2019    Bilirubin, Total 0.4 09/03/2019    Alkaline Phosphatase 160 (H) 09/03/2019    Aspartate transaminase 31 09/03/2019    Alanine transaminase 30 09/03/2019    Albumin, Serum / Plasma 3.7 04/26/2019    Int'l Normaliz Ratio 1.1 03/05/2019    Sodium, Serum / Plasma 134 (L) 04/26/2019    Potassium, Serum / Plasma 3.9 04/26/2019    Calcium, total, Serum / Plasma 9.1 04/26/2019
T8	SectionSkip 7238 7629	Lab Results   Component Value Date    Cancer Antigen 19-9 576 (H) 08/27/2019    Cancer Antigen 19-9 826 (H) 08/01/2019    Cancer Antigen 19-9 588 (H) 07/11/2019    Carcinoembryonic Antigen 16.2 (H) 08/27/2019    Carcinoembryonic Antigen 11.7 (H) 08/01/2019    Carcinoembryonic Antigen 17.0 (H) 07/11/2019     Foundation Medicine liquid biopsy results:   MSI Status Undetermined  RB1 P26fs*47
T9	SectionAnnotate 7635 7655	ASSESSMENT AND PLAN:
T10	PROBLEM 273 303	adenocarcinoma of the pancreas
T11	TEST 309 315	biopsy
T12	PROBLEM 323 369	oligo metastatic disease in the abdominal wall
T13	PROBLEM 419 433	abdominal pain
T14	PROBLEM 438 449	weight loss
T15	TEST 473 492	a CT of the abdomen
T16	PROBLEM 506 528	a mass in the pancreas
T17	PROBLEM 570 601	a concerning soft tissue nodule
T18	TEST 651 653	CT
T19	TEST 654 657	PET
T20	PROBLEM 665 719	a hypermetabolically active large pancreatic tail mass
T21	PROBLEM 759 791	the lesion in the abdominal wall
T22	PROBLEM 796 813	slightly PET avid
T23	TEST 815 818	SUV
T24	TEST 839 855	EUS directed FNA
T25	PROBLEM 859 880	the pancreatic lesion
T26	PROBLEM 905 919	adenocarcinoma
T27	PROBLEM 921 924	MSS
T28	TEST 939 970	Biopsy of abdominal wall nodule
T29	PROBLEM 978 1003	metastatic adenocarcinoma
T30	TREATMENT 1040 1055	C1D1 FOLFIRINOX
T31	TEST 1060 1064	labs
T32	PROBLEM 1074 1092	hyperbilirubinemia
T33	TEST 1094 1100	t bili
T34	PROBLEM 1138 1156	hyperbilirubinemia
T35	PROBLEM 1198 1214	Gilbert syndrome
T36	TREATMENT 1216 1226	Irinotecan
T37	TREATMENT 1258 1269	C1D1 FOLFOX
T38	TREATMENT 1284 1299	C2D1 FOLFIRINOX
T39	TEST 1301 1307	T bili
T40	TREATMENT 1365 1375	Irinotecan
T41	PROBLEM 1416 1437	irinotecan toxicities
T42	TREATMENT 1485 1495	FOLFIRINOX
T43	TEST 1509 1515	CT CAP
T44	PROBLEM 1523 1545	stable pancreatic mass
T45	PROBLEM 1550 1605	slight decreased size of anterior abdominal wall lesion
T46	ProcedureName 1646 1661	US with doppler
T47	TEST 1654 1664	doppler LE
T48	PROBLEM 1674 1760	segmental occlusive thrombi within the superior and mid duplicated left peroneal veins
T49	TREATMENT 1781 1788	xarelto
T50	TREATMENT 1807 1817	FOLFIRINOX
T51	TEST 1819 1821	CA
T52	TREATMENT 1853 1863	FOLFIRINOX
T53	TREATMENT 1882 1892	FOLFIRINOX
T54	TEST 1894 1896	CA
T55	TEST 1921 1927	CT CAP
T56	TREATMENT 1958 1967	treatment
T57	TEST 2009 2011	CA
T58	TREATMENT 2034 2043	Treatment
T59	PROBLEM 2064 2080	thrombocytopenia
T60	TEST 2082 2085	PLT
T61	TREATMENT 2107 2117	FOLFIRINOX
T62	TEST 2119 2121	CA
T63	TREATMENT 2150 2160	FOLFIRINOX
T64	TREATMENT 2174 2190	C12D1 FOLFIRINOX
T65	TEST 2216 2218	CT
T66	PROBLEM 2219 2253	CAP stable disease in the pancreas
T67	PROBLEM 2258 2279	abdominal wall lesion
T68	TREATMENT 2314 2332	chemotherapy break
T69	TREATMENT 2450 2468	surgical resection
T70	PROBLEM 2470 2487	His pancreas mass
T71	PROBLEM 2549 2577	extensive vessel involvement
T72	PROBLEM 2582 2592	encasement
T73	TREATMENT 2622 2645	consolidation radiation
T74	PROBLEM 2667 2685	his pancreas tumor
T75	PROBLEM 2728 2745	the complications
T76	TREATMENT 2815 2832	radiation therapy
T77	PROBLEM 2863 2875	asymptomatic
T78	PROBLEM 2958 2974	some oral thrush
T79	TREATMENT 2984 2995	fluconazole
T80	TREATMENT 3058 3073	cicloprox cream
T81	PROBLEM 3078 3104	tinea cruris in groin area
T82	TEST 3134 3143	point ROS
T83	TEST 3158 3175	all other systems
T84	TREATMENT 3211 3241	Current Outpatient Medications
T85	TREATMENT 3279 3306	butenafine (LOTRIMIN ULTRA)
T86	TREATMENT 3324 3339	cholecalciferol
T87	TREATMENT 3341 3351	vitamin D3
T88	TREATMENT 3414 3436	clotrimazole (MYCELEX)
T89	TREATMENT 3560 3579	chemotherapy cycles
T90	TREATMENT 3586 3603	initial treatment
T91	TREATMENT 3607 3613	Troche
T92	TREATMENT 3620 3642	fluconazole (DIFLUCAN)
T93	TREATMENT 3776 3799	hyoscyamine (LEVSIN/SL)
T94	PROBLEM 3902 3920	abdominal cramping
T95	TREATMENT 3986 3993	KERYDIN
T96	TREATMENT 3998 4075	SolA       L.acidoph/B.long/L.plant/B.lac (PROBIOTIC ACIDOPHILUS BEADS ORAL)
T97	TREATMENT 4097 4124	lidocaine-prilocaine (EMLA)
T98	TREATMENT 4169 4180	port access
T99	PROBLEM 4195 4199	pain
T100	TREATMENT 4212 4243	lipase-protease-amylase (CREON)
T101	TREATMENT 4344 4364	loperamide (IMODIUM)
T102	PROBLEM 4421 4429	diarrhea
T103	TREATMENT 4542 4562	ondansetron (ZOFRAN)
T104	PROBLEM 4621 4627	nausea
T105	PROBLEM 4632 4640	vomiting
T106	TREATMENT 4674 4694	palonosetron (Aloxi)
T107	TREATMENT 4768 4789	oxyCODONE (OXYCONTIN)
T108	TREATMENT 4936 4958	oxyCODONE (ROXICODONE)
T109	PROBLEM 5044 5048	Pain
T110	PROBLEM 5054 5077	moderate to severe pain
T111	TREATMENT 5143 5171	prochlorperazine (COMPAZINE)
T112	PROBLEM 5253 5259	nausea
T113	PROBLEM 5264 5272	vomiting
T114	TREATMENT 5338 5359	rivaroxaban (XARELTO)
T115	TREATMENT 5432 5457	terbinafine HCl (LAMISIL)
T116	TREATMENT 5587 5614	Host Defense brand "Stamets
T117	TREATMENT 5624 5638	Immune Support
T118	TREATMENT 5686 5694	infusion
T119	TREATMENT 5730 5746	royal sun blazei
T120	TREATMENT 5748 5757	cordyceps
T121	TREATMENT 5931 5939	infusion
T122	TREATMENT 5979 5990	medications
T123	PROBLEM 6058 6073	Known Allergies
T124	PROBLEM 6306 6317	Symptomatic
T125	PROBLEM 6368 6371	NAD
T126	PROBLEM 6439 6459	respiratory distress
T127	PROBLEM 6524 6526	HI
T128	PROBLEM 6528 6530	SI
T129	PROBLEM 6532 6546	hallucinations
T130	PROBLEM 6548 6556	paranoia
T131	PROBLEM 6561 6570	delusions
T132	TEST 6640 6645	Value
T133	TEST 6654 6657	WBC
T134	TEST 6658 6663	Count
T135	TEST 6682 6692	Neutrophil
T136	TEST 6693 6707	Absolute Count
T137	TEST 6727 6737	Hemoglobin
T138	TEST 6744 6745	L
T139	TEST 6761 6771	Hematocrit
T140	TEST 6795 6809	Platelet Count
T141	TEST 6815 6816	L
T142	TEST 6832 6842	Creatinine
T143	TEST 6862 6871	Bilirubin
T144	TEST 6873 6878	Total
T145	TEST 6897 6917	Alkaline Phosphatase
T146	TEST 6940 6962	Aspartate transaminase
T147	TEST 6980 7000	Alanine transaminase
T148	TEST 7018 7025	Albumin
T149	TEST 7027 7032	Serum
T150	TEST 7035 7041	Plasma
T151	TEST 7060 7065	Int'l
T152	TEST 7066 7074	Normaliz
T153	TEST 7075 7080	Ratio
T154	TEST 7099 7105	Sodium
T155	TEST 7107 7112	Serum
T156	TEST 7115 7121	Plasma
T157	TEST 7144 7153	Potassium
T158	TEST 7155 7160	Serum
T159	TEST 7163 7169	Plasma
T160	TEST 7188 7195	Calcium
T161	TEST 7204 7209	Serum
T162	TEST 7212 7218	Plasma
T163	TEST 7276 7282	Cancer
T164	TEST 7283 7290	Antigen
T165	TEST 7318 7332	Cancer Antigen
T166	TEST 7360 7374	Cancer Antigen
T167	TEST 7402 7426	Carcinoembryonic Antigen
T168	TEST 7450 7474	Carcinoembryonic Antigen
T169	TEST 7498 7522	Carcinoembryonic Antigen
T170	PROBLEM 7814 7844	adenocarcinoma of the pancreas
T171	TEST 7850 7856	biopsy
T172	PROBLEM 7864 7910	oligo metastatic disease in the abdominal wall
T173	TREATMENT 7939 7949	FOLFIRINOX
T174	PROBLEM 7955 7989	Stage IV pancreatic adenocarcinoma
T175	TREATMENT 8026 8036	FOLFIRINOX
T176	TREATMENT 8091 8109	chemotherapy break
T177	TEST 8118 8130	restaging CT
T178	TREATMENT 8259 8277	surgical resection
T179	TREATMENT 8325 8353	palliative radiation therapy
T180	PROBLEM 8357 8374	his pancreas mass
T181	TREATMENT 8413 8422	radiation
T182	PROBLEM 8453 8471	signs and symptoms
T183	PROBLEM 8475 8485	a GI bleed
T184	PROBLEM 8490 8509	other complications
T185	PROBLEM 8530 8548	his pancreas tumor
T186	PROBLEM 8674 8680	Thrush
T187	TREATMENT 8709 8720	fluconazole
T188	TEST 8741 8762	patient complete labs
T189	PROBLEM 8775 8783	diabetes
T190	PROBLEM 8796 8807	prediabetes
T191	TEST 8810 8823	blood glucose
T192	TEST 8828 8839	Hemboglobin
T193	TEST 8840 8843	A1C
T194	PROBLEM 8858 8924	thrombi within the superior and mid duplicated left peroneal veins
T195	TREATMENT 8938 8945	xarelto
T196	PROBLEM 8953 8967	Abdominal pain
T197	PROBLEM 8968 8976	cramping
T198	TREATMENT 9036 9041	Creon
T199	TREATMENT 9086 9095	Oxycontin
T200	TREATMENT 9111 9120	Oxycodone
T201	PROBLEM 9142 9145	BTP
T202	PROBLEM 9178 9189	Weight loss
T203	PROBLEM 9691 9706	Mental capacity
T204	PROBLEM 9716 9720	pain
T205	TREATMENT 9735 9751	treatment 
 plan
T206	TREATMENT 9802 9827	life sustaining treatment
T207	PROBLEM 10019 10035	any new symptoms
T208	PROBLEM 10365 10377	the symptoms
T209	TREATMENT 10379 10393	treatment plan
T210	Age 146 153	53 y.o.
T211	ClinicalCondition 273 303	adenocarcinoma of the pancreas
T212	Histology 273 287	adenocarcinoma
T213	Metastasis 323 339	oligo metastatic
T214	Site 355 369	abdominal wall
R1	SiteOf Arg1:T214 Arg2:T213	
R2	TumorDesc TumorDetails:T213 Desc:T211	
R3	TumorDesc TumorDetails:T212 Desc:T211	
T215	ProcedureName 309 315	biopsy
A1	IntentVal T215 diagnosis
A2	TreatmentTypeVal T215 others
A3	TreatmentCategory T215 Others
R4	TestOrProcedureReveals Test:T215 Desc:T213	
T216	Symptom 419 433	abdominal pain
A4	IsPresentOnFirstCancerDiagnosis T216 yes
A5	IsCausedByDiagnosedCancer T216 yes
A6	ChronicVal T216 non-chronic
T217	Symptom 438 449	weight loss
A7	IsPresentOnFirstCancerDiagnosis T217 yes
A8	IsCausedByDiagnosedCancer T217 yes
A9	ChronicVal T217 non-chronic
T218	Datetime 454 464	01/10/2019
R5	HappensBefore Arg1:T216 Arg2:T218	
R6	HappensBefore Arg1:T217 Arg2:T218	
T219	Radiology 475 492	CT of the abdomen
A10	IntentVal T219 diagnosis
R7	HappensAtOnDuring Arg1:T219 Arg2:T218	
T220	RadPathResult 508 512	mass
A11	RadPathResultVal T220 InitialCancerDiagnosis
T221	Site 520 528	pancreas
R8	SiteOf Arg1:T221 Arg2:T220	
T222	RadPathResult 572 601	concerning soft tissue nodule
A12	RadPathResultVal T222 InitialCancerDiagnosis
T223	Site 609 623	abdominal wall
T224	Laterality 627 634	midline
R9	LateralityOfSite Arg1:T224 Arg2:T223	
R10	SiteOf Arg1:T223 Arg2:T222	
R11	ResultOfTest Desc:T220 Test:T219	
R12	ResultOfTest Desc:T222 Test:T219	
R13	TestOrProcedureConductedForProblem Test:T219 Prob:T216	
R14	TestOrProcedureConductedForProblem Test:T219 Prob:T217	
T225	Datetime 641 649	02/06/19
T226	Radiology 651 657	CT PET
A13	IntentVal T226 staging
A14	RadPathResultVal T226 InitialCancerDiagnosis
T227	RadPathResult 667 698;715 748	hypermetabolically active large mass abutting adjacent structures
A15	RadPathResultVal T227 InitialCancerDiagnosis
T228	RadPathResult 763 769;796 822	lesion slightly PET avid (SUV 1.2
A16	RadPathResultVal T228 InitialCancerDiagnosis
T229	Site 699 709	pancreatic
T230	Laterality 710 714	tail
T231	Site 777 791	abdominal wall
R15	SiteOf Arg1:T231 Arg2:T228	
R16	LateralityOfSite Arg1:T230 Arg2:T229	
R17	SiteOf Arg1:T229 Arg2:T227	
R18	ResultOfTest Desc:T227 Test:T226	
R19	ResultOfTest Desc:T228 Test:T226	
T232	SectionSkip 3211 3898;3901 5849;5852 6006	Current Outpatient Medications   Medication Sig Dispense Refill    butenafine (LOTRIMIN ULTRA) 1 % cream       cholecalciferol, vitamin D3, 1000 UNITS TAB tablet Take 4 tablets by mouth daily         clotrimazole (MYCELEX) 10 mg troche 1 tablet (10 mg total) by Other route 3 (three) times daily Take by buccal route. Take for 14 days and during chemotherapy cycles after initial treatment 90 Troche 1    fluconazole (DIFLUCAN) 100 mg tablet Take 200mg PO qd on day one followed by 100mg PO qd on subsequent days.  Take for 1 week and then stop. 8 tablet 0    hyoscyamine (LEVSIN/SL) 0.125 MG SL tablet Place 1 tablet (0.125 mg total) under the tongue every 4 (four) hours as needed (abdominal cramping). (Patient not taking: Reported on 09/17/2019  ) 60 tablet 3    KERYDIN 5 % SolA       L.acidoph/B.long/L.plant/B.lac (PROBIOTIC ACIDOPHILUS BEADS ORAL) Take by mouth.      lidocaine-prilocaine (EMLA) 2.5-2.5 % cream Apply cream one hour before port access as needed for pain. 30 g 2    lipase-protease-amylase (CREON) 24,000-76,000 -120,000 unit capsule Take 2 tabs with meals and 1 tab with snacks. 300 capsule 5    loperamide (IMODIUM) 2 mg capsule Take two capsules by mouth at the onset of diarrhea, then take one capsule every 2 hours until diarrhea-free for 12 hours. 30 capsule 5    medical cannabis       ondansetron (ZOFRAN) 8 mg tablet Take 1 tablet three times a day as needed for nausea and vomiting. Start 2 days after last dose of palonosetron (Aloxi) is given. (Patient not taking: Reported on 07/25/2019  ) 30 tablet 5    oxyCODONE (OXYCONTIN) 10 mg 12 hr ER tablet Take 1 tablet (10 mg total) by mouth every 12 (twelve) hours (Patient not taking: Reported on 09/17/2019  ) 60 tablet 0    oxyCODONE (ROXICODONE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 4 (four) hours as needed for Pain (for moderate to severe pain). (Patient not taking: Reported on 09/17/2019  ) 90 tablet 0    prochlorperazine (COMPAZINE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 6 (six) hours as needed (nausea and vomiting). (Patient not taking: Reported on 09/17/2019  ) 30 tablet 5    rivaroxaban (XARELTO) 20 mg tablet Take 1 tablet (20 mg total) by mouth daily 30 tablet 5    terbinafine HCl (LAMISIL) 1 % cream Apply topically Daily. Use as instructed      TURMERIC ORAL Take by mouth      UNABLE TO FIND Take 1 tablet by mouth Host Defense brand "Stamets 7" Daily Immune Support, one tablet every other day during weeks of no infusion.   Each tablet contains 71.5 mg of royal sun blazei, cordyceps, reishi, maitake, lion's mane, chaga, and mesima.        UNABLE TO FIND Take by mouth Host Defense brand Turkey Tail extract, ~ 0.5 ml every other day during weeks of no infusion       No current facility-administered medications for this visit.
A17	SectionSkipType T232 medications
A18	SectionSkipType T5 physical_exam
A19	SectionSkipType T4 allergies
R20	HappensAtOnDuring Arg1:T226 Arg2:T225	
T233	Datetime 829 837	01/22/19
T234	ProcedureName 839 855	EUS directed FNA
A20	IntentVal T234 diagnosis
A21	TreatmentTypeVal T234 others
A22	TreatmentCategory T234 Others
T235	RadPathResult 863 873;905 919	pancreatic adenocarcinoma
A23	RadPathResultVal T235 InitialCancerDiagnosis
R21	ResultOfTest Desc:T235 Test:T234	
T236	Histology 905 919	adenocarcinoma
A24	HistoryVal T236 new
A25	EpisodeDescription T236 FirstOccurrence
T237	BiomarkerName 921 924	MSS
A26	EpisodeDescription T237 FirstOccurrence
A27	BiomarkerResultVal T237 Negative
T238	Site 863 873	pancreatic
T239	ClinicalCondition 863 873;905 919	pancreatic adenocarcinoma
A28	ContinuityVal T239 new
R22	SiteOf Arg1:T238 Arg2:T239	
A29	HistoryVal T237 new
R23	TumorDesc TumorDetails:T237 Desc:T239	
T240	BiomarkerResult 921 924	MSS
A30	EpisodeDescription T240 FirstOccurrence
A31	BiomarkerResultVal T240 Negative
R24	BiomarkerRel Arg1:T240 Arg2:T237	
R25	TumorDesc TumorDetails:T236 Desc:T239	
R26	TestOrProcedureReveals Test:T234 Desc:T239	
T241	RadPathResult 978 1003	metastatic adenocarcinoma
A32	RadPathResultVal T241 InitialCancerDiagnosis
T242	ClinicalCondition 964 1004	nodule showed metastatic adenocarcinoma.
A33	ContinuityVal T242 new
T243	Metastasis 978 988	metastatic
A34	HistoryVal T243 new
A35	EpisodeDescription T243 FirstOccurrence
T244	Histology 989 1003	adenocarcinoma
A36	HistoryVal T244 new
A37	EpisodeDescription T244 FirstOccurrence
R27	TumorDesc TumorDetails:T243 Desc:T242	
R28	TumorDesc TumorDetails:T244 Desc:T242	
T245	ProcedureName 939 945	Biopsy
A38	IntentVal T245 diagnosis
A39	TreatmentTypeVal T245 others
A40	TreatmentCategory T245 Others
R29	ResultOfTest Desc:T241 Test:T245	
T246	Datetime 929 937	02/14/19
R30	HappensAtOnDuring Arg1:T245 Arg2:T246	
R31	HappensAtOnDuring Arg1:T234 Arg2:T233	
R32	TestOrProcedureReveals Test:T245 Desc:T242	
T247	Site 949 963	abdominal wall
R33	SiteOf Arg1:T247 Arg2:T242	
T248	Datetime 1008 1016	03/08/19
T249	Cycles 1040 1044	C1D1
T250	MedicationRegimen 1045 1055	FOLFIRINOX
A41	TreatmentContinuityVal T250 planned
R34	TreatmentDesc Therapy:T250 Desc:T249	
T251	LabTestResult 1074 1092	hyperbilirubinemia
A42	IsPresentOnFirstCancerDiagnosis T251 no
A43	IsCausedByDiagnosedCancer T251 yes
A44	ChronicVal T251 non-chronic
T252	LabTestResult 1138 1156	hyperbilirubinemia
A45	ChronicVal T252 chronic
A46	ContinuityVal T252 unclear
T253	ClinicalCondition 1198 1214	Gilbert syndrome
A47	ChronicVal T253 chronic
A48	ContinuityVal T253 unclear
A49	LabTestResultVal T251 abnormal
T254	DiagnosticLabTest 1060 1064	labs
A50	IntentVal T254 others
R35	ResultOfTest Desc:T251 Test:T254	
A51	LabTestResultVal T252 abnormal
T255	MedicationName 1216 1226	Irinotecan
A52	NegationModalityVal T255 negated
A53	TreatmentTypeVal T255 maintenance
R36	NotUndergoneBecauseOf Arg1:T255 Reason:T251	
T256	Datetime 1274 1282	03/19/19
T257	Cycles 1284 1288	C2D1
T258	MedicationRegimen 1289 1299	FOLFIRINOX
A54	TreatmentContinuityVal T258 started
A55	TreatmentTypeVal T258 maintenance
R37	TreatmentDesc Therapy:T258 Desc:T257	
T259	DiagnosticLabTest 1301 1307	T bili
A56	IntentVal T259 others
T260	LabTestResult 1312 1315	0.8
A57	LabTestResultVal T260 normal
R38	ResultOfTest Desc:T260 Test:T259	
R39	HappensAtOnDuring Arg1:T258 Arg2:T256	
R40	HappensAtOnDuring Arg1:T256 Arg2:T259	
R41	BeginsOnOrAt Arg1:T250 Arg2:T248	
R42	HappensAtOnDuring Arg1:T251 Arg2:T248	
T261	MedicationName 1365 1375	Irinotecan
A58	TreatmentContinuityVal T261 started
A59	TreatmentTypeVal T261 maintenance
R43	HappensAtOnDuring Arg1:T261 Arg2:T256	
T262	Datetime 1441 1449	04/02/19
T263	Cycles 1451 1455	C3D1
T264	MedicationRegimen 1456 1466	FOLFIRINOX
A60	TreatmentContinuityVal T264 continuing
A61	TreatmentTypeVal T264 maintenance
R44	TreatmentDesc Therapy:T264 Desc:T263	
R45	HappensAtOnDuring Arg1:T264 Arg2:T262	
T265	Datetime 1470 1478	04/30/19
T266	Cycles 1480 1484	C4D1
T267	MedicationRegimen 1485 1495	FOLFIRINOX
A62	TreatmentContinuityVal T267 continuing
A63	TreatmentTypeVal T267 maintenance
A64	TreatmentIntentVal T267 palliative
A65	TreatmentIntentVal T264 palliative
A66	TreatmentIntentVal T261 palliative
A67	TreatmentCategory T261 AntiNeoPlastics
A68	TreatmentIntentVal T258 palliative
R46	TreatmentDesc Therapy:T267 Desc:T266	
R47	HappensAtOnDuring Arg1:T267 Arg2:T265	
T268	Datetime 1499 1507	05/15/19
T269	Radiology 1509 1515	CT CAP
A69	IntentVal T269 TreatmentAssessment
T270	RadPathResult 1523 1529;1541 1545	stable mass
A70	RadPathResultVal T270 DiseaseStability
T271	Site 1530 1540	pancreatic
R48	SiteOf Arg1:T271 Arg2:T270	
T272	RadPathResult 1550 1574;1599 1605	slight decreased size of lesion
A71	RadPathResultVal T272 DiseaseStability
T273	Site 1575 1598	anterior abdominal wall
R49	SiteOf Arg1:T273 Arg2:T272	
R50	ResultOfTest Desc:T272 Test:T269	
R51	ResultOfTest Desc:T270 Test:T269	
T274	Datetime 1607 1615	05/16/19
T275	Cycles 1617 1621	C5D1
T276	MedicationRegimen 1622 1632	FOLFIRINOX
A72	TreatmentContinuityVal T276 continuing
A73	TreatmentTypeVal T276 maintenance
A74	TreatmentIntentVal T276 palliative
R52	TreatmentDesc Therapy:T276 Desc:T275	
R53	HappensAtOnDuring Arg1:T276 Arg2:T274	
T277	Datetime 1636 1644	05/18/19
A75	IntentVal T46 others
A76	TreatmentTypeVal T46 others
A77	TreatmentCategory T46 Others
T278	ClinicalCondition 1674 1701	segmental occlusive thrombi
A78	ChronicVal T278 non-chronic
A79	ContinuityVal T278 new
T279	Site 1662 1664	LE
R54	SiteOf Arg1:T279 Arg2:T278	
R55	TestOrProcedureReveals Test:T46 Desc:T278	
T280	MedicationName 1781 1788	xarelto
A80	TreatmentContinuityVal T280 started
A81	TreatmentTypeVal T280 others
A82	TreatmentIntentVal T280 others
A83	TreatmentCategory T280 Others
R56	TreatmentAdministeredForProblem Treatment:T280 Prob:T278	
R57	HappensAtOnDuring Arg1:T46 Arg2:T277	
T281	Datetime 1792 1800	05/28/19
T282	Cycles 1802 1806	C6D1
T283	MedicationRegimen 1807 1817	FOLFIRINOX
A84	TreatmentContinuityVal T283 continuing
A85	TreatmentTypeVal T283 maintenance
A86	TreatmentIntentVal T283 palliative
R58	TreatmentDesc Therapy:T283 Desc:T282	
R59	HappensAtOnDuring Arg1:T283 Arg2:T281	
T284	DiagnosticLabTest 1819 1826	CA 19-9
A87	IntentVal T284 TreatmentAssessment
T285	DiagnosticLabTest 1894 1901	CA 19-9
A88	IntentVal T285 TreatmentAssessment
T286	DiagnosticLabTest 2119 2126	CA 19-9
A89	IntentVal T286 TreatmentAssessment
T287	LabTestResult 1829 1834	2,528
A90	LabTestResultVal T287 abnormal
T288	LabTestResult 1904 1907	995
A91	LabTestResultVal T288 abnormal
T289	LabTestResult 2129 2132	826
A92	LabTestResultVal T289 abnormal
R60	ResultOfTest Desc:T289 Test:T286	
R61	ResultOfTest Desc:T288 Test:T285	
R62	ResultOfTest Desc:T287 Test:T284	
R63	HappensAtOnDuring Arg1:T284 Arg2:T281	
T290	Datetime 1838 1846	06/11/19
T291	Datetime 1911 1919	07/06/19
T292	Datetime 1999 2007	07/11/19
T293	Datetime 2091 2099	08/01/19
T294	Datetime 2134 2142	08/13/19
T295	Datetime 2164 2172	09/03/19
T296	Datetime 2206 2214	09/10/19
T297	DiagnosticLabTest 2009 2016	CA 19-9
A93	IntentVal T297 TreatmentAssessment
T298	LabTestResult 2019 2022	588
A94	LabTestResultVal T298 abnormal
R64	ResultOfTest Desc:T298 Test:T297	
R65	HappensAtOnDuring Arg1:T297 Arg2:T292	
T299	Cycles 1848 1852	C7D1
T300	MedicationRegimen 1853 1863	FOLFIRINOX
A95	TreatmentContinuityVal T300 continuing
A96	TreatmentTypeVal T300 maintenance
A97	TreatmentIntentVal T300 palliative
R66	TreatmentDesc Therapy:T300 Desc:T299	
R67	HappensAtOnDuring Arg1:T300 Arg2:T290	
T301	Datetime 1867 1875	06/25/19
T302	MedicationRegimen 1882 1892	FOLFIRINOX
A98	TreatmentContinuityVal T302 continuing
A99	TreatmentTypeVal T302 maintenance
A100	TreatmentIntentVal T302 palliative
T303	Cycles 1877 1881	C8D1
R68	TreatmentDesc Therapy:T302 Desc:T303	
R69	HappensAtOnDuring Arg1:T302 Arg2:T301	
R70	HappensAtOnDuring Arg1:T285 Arg2:T301	
T304	Radiology 1921 1927	CT CAP
A101	IntentVal T304 TreatmentAssessment
T305	RadPathResult 1946 1967	response to treatment
A102	RadPathResultVal T305 TreatmentResponse
R71	ResultOfTest Desc:T305 Test:T304	
R72	HappensAtOnDuring Arg1:T304 Arg2:T291	
T306	Datetime 1970 1978	07/09/19
T307	MedicationRegimen 1985 1995	FOLFIRINOX
A103	TreatmentContinuityVal T307 continuing
A104	TreatmentTypeVal T307 maintenance
A105	TreatmentIntentVal T307 palliative
T308	Cycles 1980 1984	C9D1
R73	TreatmentDesc Therapy:T307 Desc:T308	
R74	HappensAtOnDuring Arg1:T307 Arg2:T306	
T309	Datetime 2024 2032	07/25/19
T310	Cycles 2050 2058	Cycle 10
A106	NegationModalityVal T310 negated
T311	LabTestResult 2082 2088	PLT 95
A107	LabTestResultVal T311 abnormal
T312	TreatmentType 2034 2043	Treatment
R75	TreatmentDesc Therapy:T310 Desc:T312	
R76	NotUndergoneBecauseOf Arg1:T312 Reason:T311	
T313	MedicationRegimen 2107 2117	FOLFIRINOX
A108	TreatmentContinuityVal T313 continuing
A109	TreatmentTypeVal T313 maintenance
A110	TreatmentIntentVal T313 palliative
T314	Cycles 2101 2106	C10D1
R77	TreatmentDesc Therapy:T314 Desc:T313	
R78	HappensAtOnDuring Arg1:T313 Arg2:T293	
R79	HappensAtOnDuring Arg1:T286 Arg2:T293	
T315	Cycles 2144 2149	C11D1
T316	MedicationRegimen 2150 2160	FOLFIRINOX
A111	TreatmentContinuityVal T316 continuing
A112	TreatmentTypeVal T316 maintenance
A113	TreatmentIntentVal T316 palliative
R80	TreatmentDesc Therapy:T316 Desc:T315	
R81	HappensAtOnDuring Arg1:T316 Arg2:T294	
T317	Cycles 2174 2179	C12D1
T318	MedicationRegimen 2180 2190	FOLFIRINOX
A114	TreatmentContinuityVal T318 finished
A115	TreatmentTypeVal T318 maintenance
A116	TreatmentIntentVal T318 palliative
R82	TreatmentDesc Therapy:T318 Desc:T317	
R83	HappensAtOnDuring Arg1:T318 Arg2:T295	
T319	Radiology 2216 2222	CT CAP
A117	IntentVal T319 TreatmentAssessment
T320	RadPathResult 2223 2237	stable disease
A118	RadPathResultVal T320 DiseaseStability
A119	LabTestResultVal T320 normal
T321	Site 2245 2253	pancreas
T322	Site 2258 2279	abdominal wall lesion
R84	SiteOf Arg1:T321 Arg2:T320	
R85	SiteOf Arg1:T322 Arg2:T320	
R86	ResultOfTest Desc:T320 Test:T319	
R87	HappensAtOnDuring Arg1:T319 Arg2:T296	
T323	TreatmentType 2314 2332	chemotherapy break
A120	TreatmentContinuityVal T323 started
R88	HappensAtOnDuring Arg1:T323 Arg2:T296	
T324	Datetime 2338 2346	10/03/19
T325	ProcedureName 2450 2468	surgical resection
A121	NegationModalityVal T325 hypothetical_in_future
R89	HappensAfter Arg1:T325 Arg2:T324	
T326	LocalInvasion 720 748	abutting adjacent structures
T327	ClinicalCondition 699 719	pancreatic tail mass
R90	TumorDesc TumorDetails:T326 Desc:T327	
R91	TestOrProcedureReveals Test:T226 Desc:T327	
T328	ProcedureName 2491 2505	not resectable
A122	NegationModalityVal T328 negated
A123	TreatmentCategory T328 AntiNeoPlastics
T329	LocalInvasion 2549 2592	extensive vessel involvement and encasement
A124	EpisodeDescription T329 Others
T330	ClinicalCondition 2474 2487	pancreas mass
R92	TumorDesc TumorDetails:T329 Desc:T330	
R93	NotUndergoneBecauseOf Arg1:T328 Reason:T329	
T331	Site 2474 2482	pancreas
R94	SiteOf Arg1:T331 Arg2:T330	
T332	RadiationTherapyName 2622 2645	consolidation radiation
A125	NegationModalityVal T332 hypothetical_in_future
R95	HappensAtOnDuring Arg1:T328 Arg2:T324	
T333	RadiationTherapyName 2815 2832	radiation therapy
A126	NegationModalityVal T333 negated
T334	Symptom 2863 2875	asymptomatic
A127	NegationModalityVal T334 negated
R96	NotUndergoneBecauseOf Arg1:T333 Reason:T334	
T335	LocalInvasion 2689 2709	abutting the stomach
T336	ClinicalCondition 2732 2745	complications
A128	NegationModalityVal T336 hypothetical_in_future
T337	ClinicalCondition 2680 2685	tumor
T338	Site 2671 2679	pancreas
R97	SiteOf Arg1:T338 Arg2:T337	
R98	TumorDesc TumorDetails:T335 Desc:T337	
R99	TreatmentAdministeredForProblem Treatment:T332 Prob:T335	
R100	TreatmentAdministeredForProblem Treatment:T332 Prob:T336	
T339	Symptom 2916 2939	feeling generally well.
T340	ClinicalCondition 2963 2974	oral thrush
A129	ChronicVal T340 non-chronic
A130	ContinuityVal T340 new
T341	MedicationName 2984 2995	fluconazole
A131	TreatmentContinuityVal T341 started
A132	TreatmentTypeVal T341 others
A133	TreatmentIntentVal T341 others
A134	TreatmentCategory T341 Supportive
R101	TreatmentAdministeredForProblem Treatment:T341 Prob:T340	
T342	ClinicalCondition 3078 3090	tinea cruris
A135	ChronicVal T342 non-chronic
A136	ContinuityVal T342 new
T343	Site 3094 3104	groin area
R102	SiteOf Arg1:T343 Arg2:T342	
T344	MedicationName 3058 3073	cicloprox cream
A137	TreatmentContinuityVal T344 started
A138	TreatmentTypeVal T344 others
A139	TreatmentIntentVal T344 others
A140	TreatmentCategory T344 Supportive
R103	TreatmentAdministeredForProblem Treatment:T344 Prob:T342	
T345	Age 7685 7692	53 y.o.
T346	PerformanceStatus 6302 6303	1
A141	PerformanceStatusType T346 ECOG
T347	ClinicalCondition 7814 7849;7864 7888	adenocarcinoma of the pancreas with oligo metastatic disease
A142	ContinuityVal T347 stable
T348	Histology 7814 7828	adenocarcinoma
A143	HistoryVal T348 history
T349	Metastasis 7864 7880	oligo metastatic
T350	Site 7896 7911	abdominal wall.
R104	SiteOf Arg1:T350 Arg2:T349	
R105	TumorDesc TumorDetails:T349 Desc:T347	
R106	TumorDesc TumorDetails:T348 Desc:T347	
T351	MedicationRegimen 7939 7949	FOLFIRINOX
A145	TreatmentContinuityVal T351 finished
A146	TreatmentTypeVal T351 maintenance
A147	TreatmentIntentVal T351 palliative
T352	Cycles 7926 7935	12 cycles
R107	TreatmentDesc Therapy:T352 Desc:T351	
T353	Stage 7955 7963	Stage IV
A148	HistoryVal T353 history
T354	ClinicalCondition 7964 7989	pancreatic adenocarcinoma
T355	Histology 7975 7989	adenocarcinoma
A149	HistoryVal T355 history
R108	TumorDesc TumorDetails:T355 Desc:T354	
T356	Site 7964 7974	pancreatic
R109	SiteOf Arg1:T356 Arg2:T354	
R110	TumorDesc TumorDetails:T353 Desc:T354	
T357	Cycles 8013 8022	12 cycles
T358	MedicationRegimen 8026 8036	FOLFIRINOX
A150	TreatmentContinuityVal T358 finished
A151	TreatmentTypeVal T358 maintenance
A152	TreatmentIntentVal T358 palliative
T359	Datetime 8042 8055	February 2019
T360	Datetime 8058 8069	August 2019
R111	TreatmentDesc Therapy:T358 Desc:T357	
R112	BeginsOnOrAt Arg1:T358 Arg2:T359	
R113	EndsOnOrAt Arg1:T358 Arg2:T360	
T361	TreatmentType 8091 8109	chemotherapy break
A153	NegationModalityVal T361 negated
A154	TreatmentContinuityVal T361 continuing
T362	Radiology 8118 8130	restaging CT
A155	IntentVal T362 TreatmentAssessment
T363	Datetime 8143 8151	11/19/19
A156	NegationModalityVal T362 planned_in_future
R114	HappensAtOnDuring Arg1:T362 Arg2:T363	
T364	ProcedureName 8259 8296	surgical resection is not recommended
A157	NegationModalityVal T364 negated
A158	TreatmentTypeVal T364 local
A159	TreatmentCategory T364 AntiNeoPlastics
T365	RadiationTherapyName 8325 8353;8397 8435	palliative radiation therapy not recommended radiation at this time
A160	NegationModalityVal T365 negated
A161	TreatmentTypeVal T365 local
A162	TreatmentIntentVal T365 palliative
T366	ClinicalCondition 8370 8374	mass
A163	ChronicVal T366 non-chronic
A164	ContinuityVal T366 stable
T367	Site 8361 8369	pancreas
R115	SiteOf Arg1:T367 Arg2:T366	
R116	TreatmentAdministeredForProblem Treatment:T365 Prob:T366	
T368	GenomicTest 8587 8620	Foundation Medicine liquid biopsy
A165	IntentVal T368 TreatmentAssessment
A166	GenomicTestType T368 Somatic
T369	GenomicTestResult 8632 8669	MSI Status Undetermined  RB1 P26fs*47
R117	ResultOfTest Desc:T369 Test:T368	
T370	ClinicalCondition 8674 8680	Thrush
A167	ChronicVal T370 non-chronic
A168	ContinuityVal T370 stable
T371	MedicationName 8709 8720	fluconazole
A169	NegationModalityVal T371 planned_in_future
A170	TreatmentContinuityVal T371 planned
A171	TreatmentTypeVal T371 others
A172	TreatmentIntentVal T371 others
R118	TreatmentAdministeredForProblem Treatment:T371 Prob:T370	
T372	ClinicalCondition 8796 8807	prediabetes
A173	ChronicVal T372 chronic
A174	ContinuityVal T372 unclear
T373	DiagnosticLabTest 8828 8843	Hemboglobin A1C
A175	NegationModalityVal T373 planned_in_future
T374	DiagnosticLabTest 8810 8823	blood glucose
A176	NegationModalityVal T374 planned_in_future
T375	ClinicalCondition 8848 8865	occlusive thrombi
A177	ChronicVal T375 non-chronic
A178	ContinuityVal T375 unclear
T376	Site 8877 8924	superior and mid duplicated left peroneal veins
R119	SiteOf Arg1:T376 Arg2:T375	
T377	MedicationName 8938 8945	xarelto
A179	TreatmentContinuityVal T377 continuing
A180	TreatmentTypeVal T377 others
A181	TreatmentIntentVal T377 others
A182	TreatmentCategory T377 Others
R120	TreatmentAdministeredForProblem Treatment:T377 Prob:T375	
T378	Frequency 8946 8948	QD
R121	Temporal Arg1:T378 Arg2:T377	
T379	Symptom 8953 8976	Abdominal pain/cramping
A183	IsPresentOnFirstCancerDiagnosis T379 yes
A184	IsCausedByDiagnosedCancer T379 yes
A185	ChronicVal T379 chronic
A186	ContinuityVal T379 improving
T380	MedicationName 9036 9041	Creon
A187	TreatmentContinuityVal T380 continuing
A188	TreatmentTypeVal T380 others
A189	TreatmentCategory T380 Supportive
T381	Frequency 9045 9076	2 or 3 tab/meal and 1 tab/snack
R122	Temporal Arg1:T381 Arg2:T380	
T382	MedicationName 9086 9095	Oxycontin
A190	TreatmentContinuityVal T382 continuing
A191	TreatmentTypeVal T382 others
A192	TreatmentIntentVal T382 others
A193	TreatmentCategory T382 Supportive
T383	TreatmentDosage 9096 9100	10mg
T384	Frequency 9104 9107	bid
R123	TreatmentDesc Therapy:T383 Desc:T382	
R124	Temporal Arg1:T384 Arg2:T382	
T385	MedicationName 9111 9120	Oxycodone
A194	TreatmentContinuityVal T385 continuing
A195	TreatmentTypeVal T385 others
A196	TreatmentIntentVal T385 others
A197	TreatmentCategory T385 Supportive
T386	TreatmentDosage 9121 9130	5 to 10mg
T387	Frequency 9134 9137	q4h
R125	TreatmentDesc Therapy:T386 Desc:T385	
R126	Temporal Arg1:T387 Arg2:T385	
T388	Symptom 9178 9189	Weight loss
A198	IsPresentOnFirstCancerDiagnosis T388 yes
A199	IsCausedByDiagnosedCancer T388 yes
A200	ChronicVal T388 chronic
A201	ContinuityVal T388 improving
T389	SectionSkip 3211 3898;3901 5849;5852 6005	Current Outpatient Medications   Medication Sig Dispense Refill    butenafine (LOTRIMIN ULTRA) 1 % cream       cholecalciferol, vitamin D3, 1000 UNITS TAB tablet Take 4 tablets by mouth daily         clotrimazole (MYCELEX) 10 mg troche 1 tablet (10 mg total) by Other route 3 (three) times daily Take by buccal route. Take for 14 days and during chemotherapy cycles after initial treatment 90 Troche 1    fluconazole (DIFLUCAN) 100 mg tablet Take 200mg PO qd on day one followed by 100mg PO qd on subsequent days.  Take for 1 week and then stop. 8 tablet 0    hyoscyamine (LEVSIN/SL) 0.125 MG SL tablet Place 1 tablet (0.125 mg total) under the tongue every 4 (four) hours as needed (abdominal cramping). (Patient not taking: Reported on 09/17/2019  ) 60 tablet 3    KERYDIN 5 % SolA       L.acidoph/B.long/L.plant/B.lac (PROBIOTIC ACIDOPHILUS BEADS ORAL) Take by mouth.      lidocaine-prilocaine (EMLA) 2.5-2.5 % cream Apply cream one hour before port access as needed for pain. 30 g 2    lipase-protease-amylase (CREON) 24,000-76,000 -120,000 unit capsule Take 2 tabs with meals and 1 tab with snacks. 300 capsule 5    loperamide (IMODIUM) 2 mg capsule Take two capsules by mouth at the onset of diarrhea, then take one capsule every 2 hours until diarrhea-free for 12 hours. 30 capsule 5    medical cannabis       ondansetron (ZOFRAN) 8 mg tablet Take 1 tablet three times a day as needed for nausea and vomiting. Start 2 days after last dose of palonosetron (Aloxi) is given. (Patient not taking: Reported on 07/25/2019  ) 30 tablet 5    oxyCODONE (OXYCONTIN) 10 mg 12 hr ER tablet Take 1 tablet (10 mg total) by mouth every 12 (twelve) hours (Patient not taking: Reported on 09/17/2019  ) 60 tablet 0    oxyCODONE (ROXICODONE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 4 (four) hours as needed for Pain (for moderate to severe pain). (Patient not taking: Reported on 09/17/2019  ) 90 tablet 0    prochlorperazine (COMPAZINE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 6 (six) hours as needed (nausea and vomiting). (Patient not taking: Reported on 09/17/2019  ) 30 tablet 5    rivaroxaban (XARELTO) 20 mg tablet Take 1 tablet (20 mg total) by mouth daily 30 tablet 5    terbinafine HCl (LAMISIL) 1 % cream Apply topically Daily. Use as instructed      TURMERIC ORAL Take by mouth      UNABLE TO FIND Take 1 tablet by mouth Host Defense brand "Stamets 7" Daily Immune Support, one tablet every other day during weeks of no infusion.   Each tablet contains 71.5 mg of royal sun blazei, cordyceps, reishi, maitake, lion's mane, chaga, and mesima.        UNABLE TO FIND Take by mouth Host Defense brand Turkey Tail extract, ~ 0.5 ml every other day during weeks of no infusion       No current facility-administered medications for this visit
A202	SectionSkipType T389 medications
T390	LocalInvasion 535 542	encased
A203	EpisodeDescription T390 FirstOccurrence
T391	Site 547 558	celiac axis
R127	SiteOf Arg1:T391 Arg2:T390	
T392	Metastasis 572 601	concerning soft tissue nodule
A204	NegationModalityVal T392 uncertain_in_present
R128	TestOrProcedureReveals Test:T219 Desc:T390	
A205	TreatmentTypeVal T250 maintenance
A206	TreatmentIntentVal T250 palliative
T393	MedicationRegimen 1263 1269	FOLFOX
A207	TreatmentContinuityVal T393 started
A208	TreatmentTypeVal T393 maintenance
A209	TreatmentIntentVal T393 palliative
T394	Cycles 1258 1262	C1D1
R129	TreatmentDesc Therapy:T394 Desc:T393	
T395	ClinicalCondition 1427 1437	toxicities
A210	NegationModalityVal T395 hypothetical_in_future
A211	ChronicVal T395 chronic
R130	ConditionOrTreatmentCausesProblem Treatment:T261 Prob:T395	
R131	HappensAtOnDuring Arg1:T268 Arg2:T269	
T396	Site 1713 1760	superior and mid duplicated left peroneal veins
R132	SiteOf Arg1:T396 Arg2:T278	
R133	ExclusionCriteriaFor Arg1:T311 Arg2:T312	
T397	DiseaseState 2223 2237	stable disease
A212	DiseaseStateVal T397 stability
A213	IntentVal T328 treatment-curative
A214	TreatmentTypeVal T328 local
A215	NegationModalityVal T339 negated
T398	SectionSkip 6306 6570	Symptomatic but completely ambulatory  Constitutional:  WDWN, NAD, pleasant and conversant   Eyes: sclera anicteric  Respiratory: no respiratory distress  Neurologic: Alert & oriented x 3  Psychiatric: Mood stable. No HI, SI, hallucinations, paranoia, or delusions
A216	SectionSkipType T398 physical_exam
A144	EpisodeDescription T349 Progression
T399	Symptom 8477 8485	GI bleed
A217	NegationModalityVal T399 hypothetical_in_future
T400	LocalInvasion 8558 8564	invade
A218	NegationModalityVal T400 hypothetical_in_future
T401	Site 8574 8582	stomach.
R134	SiteOf Arg1:T401 Arg2:T400	
T402	ClinicalCondition 8534 8548	pancreas tumor
R135	ConditionOrTreatmentCausesProblem Treatment:T402 Prob:T399	
T403	ClinicalCondition 8775 8783	diabetes
A219	NegationModalityVal T403 uncertain_in_present
R136	TreatmentAdministeredForProblem Treatment:T380 Prob:T379	
R137	TreatmentAdministeredForProblem Treatment:T382 Prob:T379	
R138	TreatmentAdministeredForProblem Treatment:T385 Prob:T379	
T404	Datetime 9867 9875	11/21/19
T405	Symptom 10023 10035	new symptoms
A220	NegationModalityVal T405 hypothetical_in_future
T406	hpi_start 107 114	PATIENT
T407	hpi_end 3100 3105	area.
T408	ap_start 7635 7645	ASSESSMENT
T409	ap_end 10109 10112	me.
R139	HappensAtOnDuring Arg1:T249 Arg2:T248	
R140	BeginsOnOrAt Arg1:T393 Arg2:T248	
R141	EndsOnOrAt Arg1:T296 Arg2:T318	
